Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Documentation of the effect of an direct or overlapping switch from another dopamine agonist
to Sifrol® on motor function, psychopathological disturbances and mood, assessment of the
reasons for the switch and the reasons for using Sifrol®, equivalent doses at the end of the
switch and tolerability of Sifrol® in ambulatory patients suffering from idiopathic
Parkinson's disease under routine conditions